Roche (OTCMKTS:RHHBY) Sets New 12-Month High – Should You Buy?

Roche Holding AG (OTCMKTS:RHHBY) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $60.22 and last traded at $60.10, with a volume of 1283862 shares. The stock had previously closed at $58.51.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Barclays raised Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Citigroup initiated coverage on shares of Roche in a research report on Tuesday, January 27th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Jefferies Financial Group lowered Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Roche in a report on Wednesday, February 4th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $57.00.

Roche Stock Performance

The company has a current ratio of 1.38, a quick ratio of 1.02 and a debt-to-equity ratio of 0.72. The stock has a 50-day moving average price of $54.39 and a 200 day moving average price of $47.09.

Institutional Investors Weigh In On Roche

Several large investors have recently modified their holdings of the company. Boston Common Asset Management LLC raised its holdings in Roche by 1.9% during the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock worth $15,049,000 after purchasing an additional 6,720 shares in the last quarter. Altrius Capital Management Inc increased its position in Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock worth $8,290,000 after purchasing an additional 7,659 shares during the period. Bard Financial Services Inc. raised its stake in shares of Roche by 1.3% during the 3rd quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock worth $5,797,000 after buying an additional 1,800 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Roche by 1.1% in the 2nd quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock valued at $4,422,000 after buying an additional 1,228 shares during the period. Finally, Meritage Portfolio Management purchased a new stake in shares of Roche in the fourth quarter valued at approximately $4,372,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.